Tucatinib usage and dosage guidance

Tucatinib is a prescription drug mainly used to treat HER2-positive breast cancer. Tucatinib is an oral tablet that should be swallowed whole and avoid chewing, crushing, or splitting. Do not take if tablet breaks. It is recommended that patients take it at the same time every day, and the interval between two doses should be about 12 hours. You can choose to take it with or without food, but it's best to keep your dosing times consistent. To deal with special circumstances, such as the patient vomiting or missing a dose of tucatinib, it is recommended to take the next dose at the regular time and not to take additional doses.

The recommended dose of tucatinib is 300 mg twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity.

During treatment, if adverse reactions occur, doctors may adjust the dosage of tucatinib based on the patient's specific conditions. The dose adjustment should follow the principle of gradual reduction. The initial dose is reduced to 250mg twice a day; if it is still intolerable, it can be further reduced to 200mg or 150mg twice a day. If a patient is unable to tolerate a dose of 150 mg, permanent discontinuation of tucatinib should be considered.

The use of tucatinib in combination with capecitabine and trastuzumab is not recommended in patients with severe renal insufficiency (creatinine clearance<30 mL/min). No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30-89 mL/min).

Before using tucatinib, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, vitamins, herbal medicines, etc., to avoid drug-drug interactions. During treatment, patients should undergo regular blood tests, liver function tests, etc. to monitor the efficacy and adverse reactions of the drug. At the same time, patients should pay close attention to changes in their symptoms and report any discomfort to their doctors in a timely manner. The drug may cause adverse reactions in nursing infants, and it is recommended to avoid breastfeeding while taking the drug and for one week after the last dose.

References:

https://www.drugs.com/dosage/tukysa.html